Email from CEO Angel February 7th 2013. Response to rick25.
Hi Richard,
Thanks, as always, for reaching out. I do understand that we've been silent on the PR side, but that's not for any reason in particular. There is progress, just not progress worthy of a PR (yet). There is no reason to push fluff. Here's a basic overview of what's occurring with the company. Feel free to share amidst colleagues. This contains no proprietary or definitive forward-looking statements, nor is it meant to be perceived as such.
- Testing services continue as a revenue source. However, our future expansion plans are where the real revenue is. Testing is (and has alway been) just "step one". Analytical testing is our platform for valuable data collection, which in turn drives BGMT's business strategy.
- BGMT's future expansion plans require additional capital reserves beyond current revenue sources to implement. This was expressed in recent financials as well. Simply, technology is expensive to build. Great technology is very expensive to build. We've accomplished our initial goals of branding and dominance in the marketplace. Now it's time to get larger investment groups involved.
There are two ways to raise capital via a public company... a) on the back of the shareholders through dilution or direct stock sale, OR, b) through private capital raise via company equity (thus minimizing dilution). The company has never once utilized the existing shareholder base as a means to raise capital. This is the type of volatility introduced by the previous RightSmile management that we've looked to avoid creating in the marketplace. Path "B" is our focus, as it benefits all current shareholders. We also have strong preferred stock reserves to implement this. However, this path takes time and is often a moving target. The new laws in CO and WA have greatly assisted our efforts and we continue to push forward.
As I'm sure you know, any investment from current shareholders is only shared among the "trading marketplace". BGMT has never seen one spendable dollar from the shareholder base. BGMT receives no benefit from the publicly traded shares, as neither BGMT nor its principals have ever sold a share.
Once these processes are complete, we move forward with the full audit, and uplisting. A new S1 on the QB is expected to benefit all shareholders.
- I mentioned a year ago about BGMT's plans to enter the mobile health and mobile health device market. This continues to be our next product evolution for the alternative care marketplace. We've identified the technology, and we've identified our knowledge sources (IP). It's a hot market, and a hot product. As I predicted, this is one of the biggest tech buzzes now. It will take about 12 months of development to complete, with a prototype available around roughly the 6 month period. That timer starts once we have the resources aboard that we need to embrace full-fledged R&D. Impressive board members and executive appointments are also pending as we move forward along this tract. Much is in alignment. You will see these as future PRs, bearing that all continues to go to plan.
- We've also recently identified a new product strategy that we expect to bring in a new revenue stream, likely within several months of signed agreements. This involves the production of a new nutraceutical product, specific to the cannabis industry. It is unlike any product that our competitors have released or have spoken about thus far. However, it's too early to tell if we'll even pull the trigger on this. We're in the phase of legal due diligence and intellectual property negotiations. We are truly at a 50/50 stage right now, and the project could be shelved just as easily as it may be adopted. I'm quite particular about what projects we bring on board, and I've passed on various opportunities in the past few months. However, if we do move forward with this, it will be absolutely fantastic. But all public disclosures considered, I am not saying that we will or we won't -- only that BGMT is exploring options. We continue to explore several options to boost shareholder value and ongoing revenues.
FYI -- you can begin to perceive the related emerging strategy with this previously released news:
Hi Richard,
Thanks, as always, for reaching out. I do understand that we've been silent on the PR side, but that's not for any reason in particular. There is progress, just not progress worthy of a PR (yet). There is no reason to push fluff. Here's a basic overview of what's occurring with the company. Feel free to share amidst colleagues. This contains no proprietary or definitive forward-looking statements, nor is it meant to be perceived as such.
- Testing services continue as a revenue source. However, our future expansion plans are where the real revenue is. Testing is (and has alway been) just "step one". Analytical testing is our platform for valuable data collection, which in turn drives BGMT's business strategy.
- BGMT's future expansion plans require additional capital reserves beyond current revenue sources to implement. This was expressed in recent financials as well. Simply, technology is expensive to build. Great technology is very expensive to build. We've accomplished our initial goals of branding and dominance in the marketplace. Now it's time to get larger investment groups involved.
There are two ways to raise capital via a public company... a) on the back of the shareholders through dilution or direct stock sale, OR, b) through private capital raise via company equity (thus minimizing dilution). The company has never once utilized the existing shareholder base as a means to raise capital. This is the type of volatility introduced by the previous RightSmile management that we've looked to avoid creating in the marketplace. Path "B" is our focus, as it benefits all current shareholders. We also have strong preferred stock reserves to implement this. However, this path takes time and is often a moving target. The new laws in CO and WA have greatly assisted our efforts and we continue to push forward.
As I'm sure you know, any investment from current shareholders is only shared among the "trading marketplace". BGMT has never seen one spendable dollar from the shareholder base. BGMT receives no benefit from the publicly traded shares, as neither BGMT nor its principals have ever sold a share.
Once these processes are complete, we move forward with the full audit, and uplisting. A new S1 on the QB is expected to benefit all shareholders.
- I mentioned a year ago about BGMT's plans to enter the mobile health and mobile health device market. This continues to be our next product evolution for the alternative care marketplace. We've identified the technology, and we've identified our knowledge sources (IP). It's a hot market, and a hot product. As I predicted, this is one of the biggest tech buzzes now. It will take about 12 months of development to complete, with a prototype available around roughly the 6 month period. That timer starts once we have the resources aboard that we need to embrace full-fledged R&D. Impressive board members and executive appointments are also pending as we move forward along this tract. Much is in alignment. You will see these as future PRs, bearing that all continues to go to plan.
- We've also recently identified a new product strategy that we expect to bring in a new revenue stream, likely within several months of signed agreements. This involves the production of a new nutraceutical product, specific to the cannabis industry. It is unlike any product that our competitors have released or have spoken about thus far. However, it's too early to tell if we'll even pull the trigger on this. We're in the phase of legal due diligence and intellectual property negotiations. We are truly at a 50/50 stage right now, and the project could be shelved just as easily as it may be adopted. I'm quite particular about what projects we bring on board, and I've passed on various opportunities in the past few months. However, if we do move forward with this, it will be absolutely fantastic. But all public disclosures considered, I am not saying that we will or we won't -- only that BGMT is exploring options. We continue to explore several options to boost shareholder value and ongoing revenues.
FYI -- you can begin to perceive the related emerging strategy with this previously released news:
